Trillium Therapeutics: A Preclinical Cancer Immunotherapy Company With A Promising Lead Compound
- Trillium Therapeutics' lead compound is SIRPαFc, which blocks CD47, the "don’t eat me" signal on cancer cells which prevents immune-mediated cancer cell killing.
- The fusion protein SIRPαFc may have a superior safety profile compared to antibody approaches of blocking CD47, due to reduced red blood cell binding.
- An IND for acute myeloid leukemia is expected in mid-2015, but SIRPαFc has broad anti-cancer potential as a monotherapy and used in combination.
- In December 2013, Trillium Therapeutics raised $33M from a private placement with prominent US healthcare funds, which is expected to fund SIRPαFc through IND-enabling studies, manufacturing, and Phase 1 clinical.